Press releases

As the pharmaceutical industry gathered at CPHI Milan 2026 this week, formulation challenges associated with increasingly complex drug compounds were clearly part of the broader industry conversation. Poor aqueous solubility remains one of the most persistent challenges in small molecule drug development. But the discussion around formulation...

Disruptive Pharma will attend CPHI Milan on 6–8 October, one of the pharmaceutical industry’s leading global events, bringing together companies from across the pharma value chain. Peter Åsberg, CEO of Disruptive Pharma, will be at CPHI to meet with current and potential partners and discuss opportunities around Formulite®, our formulation...

Disruptive Pharma AB (publ) ("Disruptive Pharma" or the "Company") today announced that it has entered into an agreement to sell the GTX platform to a wholly owned subsidiary of Aurelia Invest AB ("Aurelia"). The transaction is the result of the process initiated in June 2026 to evaluate strategic alternatives for the GTX platform, which was...

We are pleased to welcome Tobias Assander to Disruptive Pharma as Formulite® Manufacturing and Process Development Lead. Tobias brings broad experience from the pharmaceutical industry and will lead activities related to process development, scale-up and manufacturing of Formulite®. His role will be important as we continue strengthening...

Evelina Meurling and Ellen Brunzell will represent Disruptive Pharma at the SweDeliver Summit 2026, an annual meeting bringing together academia and industry in drug delivery and pharmaceutical development. The SweDeliver network provides an important forum for exchanging experience, sharing perspectives and staying closely connected to developments...